Oura goes public, Ring 5 ships, BP claims flood in

Oura Ring 5 Launches, Files for IPO, and Enters the BP Sensor Wars

• Oura launched Ring 5 today, shipping June 4 — 40% smaller than Gen 4, with redesigned low-profile sensor domes and 12 stronger signal pathways for accuracy across diverse skin tones; IP68/100m water rating; $399 base finishes, $499 premium; membership drops to $5.99/month or $69.99/year; HSA/FSA eligible (BusinessWire announcement).

• Health Radar software ships with Ring 5 (and extends to Gen 3/4 rings) with nighttime blood pressure pattern signals for cardiovascular strain detection — not cuff-equivalent measurement — plus a 30-day rolling breathing disturbance view, live running/cycling/strength tracking, a GLP-1 medication management module, and an IRB-approved Brain Health Study pairing cognitive assessments with biometrics (Fitt Insider coverage). Oura also partnered with telehealth platform Counsel Health for licensed provider access inside the app across 43 U.S. states.

• Oura filed a confidential IPO prospectus with the SEC last week with no public timeline; the company projects ~$2B in 2026 revenue, is on track to surpass 5M paid members this quarter (4× growth in two years), and holds an 80% subscription renewal rate (CNBC on the filing). Last valuation: $11B (Series E, October 2025).

• FDA's January 2026 wellness guidance triggered immediate roadmap pivots — Oura's CMO confirmed timing; Samsung and others are also shipping cuffless BP estimates as wellness features with no clinical validation benchmark required, a gap STAT frames as an emerging consumer confusion risk (STAT investigation). WHOOP's FDA warning letter for its BP feature — still unresolved, reported last issue — now sits in a more permissive regulatory context than when it was issued.

---

Fitbit Air Gets Stress-Tested; Luna Band Enters; Garmin CIRQA Listing Debunked

• DC Rainmaker's first in-depth Fitbit Air review finds HR deviates 20–40 bpm on indoor trainers and outdoor cycling due to light leakage from the thin band form factor; GPS fails to log in some manually started sessions; AI coaching produces "hallucinations" that latch onto user phrasing; Google has published a fix roadmap (DC Rainmaker review). The review still recommends Fitbit Air for most users at $99, calling AI coaching "a different league" — WHOOP outperforms on HR accuracy across most tested scenarios.

• Luna Band is now official at $149 with no subscription, launching end of July 2026 in an invite-only Drop 1 — the differentiator is voice-first design using Siri to log meals, symptoms, and moments without opening an app, with LifeOS AI generating hourly personalized health plans from continuous biometrics, blood markers, and medical context (Tech Advisor). Includes haptic feedback and fertility tracking; Android support lacks voice functionality due to Siri dependency.

• A Ukrainian retailer's Garmin CIRQA listing claiming SmO2 muscle-oxygen tracking is likely fabricated — no Garmin optical wearable or regulatory filing includes SmO2, a spec grey-market resellers commonly add for credibility; the product image is an unverified mockup (the5krunner analysis). CIRQA still appears on track to launch within weeks based on Garmin Connect app code found last week, but no confirmed MSRP exists.

• Apple's own top executive wears a WHOOP — cited in a Bloomberg report as evidence of a broader Apple Watch health sensing stall as WHOOP, Oura, and Fitbit Air advance on biometric depth (Entrepreneur on Apple Watch).

---

PBM: Parkinson's Phase 3 Results, a Personalized Protocol Device, and the Evidence Debate

• Top-line results from the Celeste Phase 3 Parkinson's trial were presented at the World Parkinson Congress on May 26 — a completed 351-person double-blind RCT; the device holds FDA Breakthrough Designation (Parkinson's News Today). Celeste uses circadian light therapy — modulating the brain's clock via retinal photoreceptors — a mechanistically distinct approach from the 650–850nm mitochondrial PBM reported in prior issues; specific efficacy results were not detailed in available reporting.

• Ultrahuman launched Photon, a $249 home device at 660nm + 850nm that personalizes session timing and duration using Ring Pro and Ring Air recovery and sleep data — the first consumer PBM device integrating biometric feedback loops rather than fixed treatment schedules; ships June 2026 (Times of India coverage). No clinical validation has been published for the personalized protocol approach; wavelengths fall within established efficacy ranges.

• An epidemiologist writing in The Guardian concluded PBM evidence is "remarkably weak" across most marketed applications — thousands of trials exist but most are small, uncontrolled, and impossible to blind; the strongest signals remain acne and wound healing; wrinkle and pain claims are unsupported (The Guardian critique). NPR, CNN, and New Scientist have reported the same conclusion in prior issues; AMD and androgenetic alopecia carry more robust backing than the claims this piece focuses on.

---

Recovery Economy Scales: Contrast Therapy Franchises; AI CGM Reaches Dexcom

• Plunge House launched the first contrast therapy franchise model at $600K–$900K per franchise using a standardized 28-pool facility format; the global contrast therapy market is estimated at $16.8B in 2026, up from $15.4B, with North America as the largest revenue region (FranchiseWire). The franchise structure signals the category transitioning from boutique operators to standardized mass-market infrastructure.

• Signos raised $20M and signed a Dexcom distribution deal, placing its FDA-cleared AI CGM coaching platform in Dexcom's direct-to-consumer channel; co-investors include GV and Blue Cross Blue Shield Alabama — adding both a major CGM hardware partner and an insurance-side validator to the metabolic coaching stack (CNBC on the deal).